2) We have other programs on amyloidosis still available for 🆓credit at https://t.co/41keu1YH9J; this is currently a very HOT 🔥area with both more sensitive diagnostic testing and new, highly 🎯disease-modifying therapy #DMT.#cardioX #cardiotwitter #FOAMed #MedTwitter #MedEd
— cardio-met (@cardiomet_CE) November 17, 2025
4) This program is intended for #HCPs and is supported by an independent educational grant from BridgeBio. Statement of #accreditation and faculty disclosures are at https://t.co/gvXca4GHMU. Follow this 🧵for your 🆓0.75hr CE/#CME!
— cardio-met (@cardiomet_CE) November 17, 2025
6a) For these #AHA25 highlights, @MarthaGrogan1 & @MasriAhmadMD start by focusing on #stabilizers, which bind to the #TTR tetramer, preventing it from dissociating into its individual monomers–and those monomers are the ones that can misfold.
— cardio-met (@cardiomet_CE) November 17, 2025
6c) What #TTR variant is most common in Blacks in the United States🇺🇸 ?
— cardio-met (@cardiomet_CE) November 17, 2025
7) At #AHA25, we saw multiple new analyses of the Ph 3 #ATTRibute_CM trial data (https://t.co/VgFpNjqqbD). There were new patient subsets, new data on #mortality and #CV #hospitalization, & also long-term data from an ongoing open-label extension #OLE. pic.twitter.com/dY4VRXJRW1
— cardio-met (@cardiomet_CE) November 17, 2025
8b) @KMAlexanderMD @MargotDavisMD et al eval'd #acoramidis efficacy in ATTRwt-CM & ATTRv-CM, & variant subgroups (p.Val142Ile& non-p.Val142Ile), in the trial and in the #OLE .
— cardio-met (@cardiomet_CE) November 17, 2025
8d) Here are the study+OLE design, which prespecified capture of 1st #CV hosp #CVH to 30mos & all-cause #mortality #ACM to 42mos by genotype (captured at randomization), along with baseline characteristics: pic.twitter.com/F9pdd56kkD
— cardio-met (@cardiomet_CE) November 17, 2025
8f) A similar post-hoc analysis was performed for the 35 patients with #V142I variant demonstrating a 69% risk reduction (HR 0.31, 95% CI 0.21-0.81) with #acoramidis vs placebo for #ACM/ First #CVH through month 30. pic.twitter.com/042PKYmHc8
— cardio-met (@cardiomet_CE) November 17, 2025
8h) @MarthaGrogan1 sums up: these data ➡️consistent benefit of #acoramidis in #ATTR-CM whether #ATTRwt or #ATTRv & in (post-hoc) pts in V142I subgroup. These observations merit further characterization in larger studies, esp given the high event rate & unmet need in ATTRv.
— cardio-met (@cardiomet_CE) November 17, 2025
10a) First, @MathewMaurer et al showed pts w/#AF at baseline usually had lower #6MWD & #KCCQ_OS scores & higher #NTPBNP. pic.twitter.com/nVMl6HYAhv
— cardio-met (@cardiomet_CE) November 17, 2025
10c) The limitations of this analysis include lack of randomization according to #AF/#AFL at baseline and that AF/AFL occurrence was not assessed as a time-dependent variable. pic.twitter.com/Q6w3NU6Mzd
— cardio-met (@cardiomet_CE) November 17, 2025
12) Third, @cardiomet_ce faculty @Ron_Witteles et al presented a post-hoc analysis of #ACM/First #CVH in pts who were early-stage #HF–NYHA class I or II–at baseline. Similar risk reduction was seen with #acoramidis in those with and without #AF at 30 and 42 months. pic.twitter.com/buv0Ivy0xF
— cardio-met (@cardiomet_CE) November 17, 2025
14) In summary, per @MarthaGrogan1, #AHA25 data on the #TTR #stabilizer #acoramidis ➡️ significant ⬇️in #ACM and first #CVH across diverse pre-specified & post-hoc subgroups in #ATTRribute_CM, including in the high-risk variant populations (e.g., p.V142I/V122I).
— cardio-met (@cardiomet_CE) November 17, 2025
15b) #TTR gene #silencers (#siRNA or #ASOs) work by targeting the #mRNA that carries instructions for making the TTR protein in the liver, preventing its production, and thereby reducing the harmful amyloid deposits of misfolded fibrils in ATTR.
— cardio-met (@cardiomet_CE) November 17, 2025
17a) Jering et al evaluated left atrial #LA function & size in the #HELIOS_B trial. LA dysfunction as measured by #strain is common in #ATTR_CM, & worsening LA strain correlated with advancing #cardiomyopathy. pic.twitter.com/UcLqhCVqGk
— cardio-met (@cardiomet_CE) November 17, 2025
18a) So while we're talking about #strain–how about the #RV? Turns out RV dysfunction is common in #ATTR_CM, & when assessed by RV free wall strain (#RVFWS) is strongly & independently associated w/⬆️risk of #ACM & recurrent CV events. Per Jering et al at #AHA2025: pic.twitter.com/rnwCPZVyuQ
— cardio-met (@cardiomet_CE) November 17, 2025
19) Summed up by @MasriAhmadMD, in #HELIOS_B analyses presented at #AHA2025.#vutrisiran showed significant, sustained reductions in #ACM & #CV events, along with improvements in heart structure, function, and renal health.
— cardio-met (@cardiomet_CE) November 17, 2025
20b) #Depleters are #MAbs that target and remove removing misfolded #TTR amyloid fibrils that build up in the myocardium & other tissues. They bind directly to existing amyloid deposits, allowing clearance of these harmful aggregates. This could be esp imp't in advanced ATTR-CM.
— cardio-met (@cardiomet_CE) November 17, 2025
21b) At baseline, this was a typical contemporary #ATTR-CM population, majority of pts were treated with #TTR-targeted therapies. Results: improvement in #NTPBNP, but not #6MWT; mixed findings on echo parameters & MRI in a subset. Safety overall ok, but w/ ?? re arrhythmia EP. pic.twitter.com/tMjDoV2and
— cardio-met (@cardiomet_CE) November 17, 2025
22b) The trial recruited pts over multiple parts, including an ascending dose cohort & an expansion cohort with 55 mg which is being used now in the first Ph 3trial, then long-term follow up.
— cardio-met (@cardiomet_CE) November 17, 2025
Single administration of Nex-Z led to significant >90% ⬇️in circulating #TTR levels. pic.twitter.com/4gWqr4s1Vs
23) Sooooo . . . A LOT of #ATTR_CM data at #AHA24! The field is moving rapidly and no doubt we'll see more new data at #ACC25! You just earned 0.75hr 🆓 CE/#CME & you can grab your certificate at https://t.co/AsOSdcb2PO.
— cardio-met (@cardiomet_CE) November 17, 2025
Huge thanks to @MarthaGrogan1 & @MasriAhmadMD !